Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19

Chiara Bruzzone; Ricardo Conde; Nieves Embade; José M Mato; Oscar Millet

doi:10.3389/fmolb.2023.1111482

Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19

Front Mol Biosci. 2023 Feb 15:10:1111482. doi: 10.3389/fmolb.2023.1111482. eCollection 2023.

Authors

Chiara Bruzzone¹, Ricardo Conde¹, Nieves Embade¹, José M Mato^{1

2}, Oscar Millet^{1

2}

Affiliations

¹ Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bilbao, Bizkaia, Spain.
² CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.

Abstract

COVID-19 currently represents one of the major health challenges worldwide. Albeit its infectious character, with onset affectation mainly at the respiratory track, it is clear that the pathophysiology of COVID-19 has a systemic character, ultimately affecting many organs. This feature enables the possibility of investigating SARS-CoV-2 infection using multi-omic techniques, including metabolomic studies by chromatography coupled to mass spectrometry or by nuclear magnetic resonance (NMR) spectroscopy. Here we review the extensive literature on metabolomics in COVID-19, that unraveled many aspects of the disease including: a characteristic metabotipic signature associated to COVID-19, discrimination of patients according to severity, effect of drugs and vaccination treatments and the characterization of the natural history of the metabolic evolution associated to the disease, from the infection onset to full recovery or long-term and long sequelae of COVID.

Keywords: COVID-19; LC/GC-MS; NMR; SARS-CoV-2 infection; lipidomics; long covid; metabolomics; phenoreversion.

Publication types

Review

Grants and funding

This research was funded by the SPRI I + D COVID-19 fund (Basque Government, bG-COVID-19), BIOEF EITB Maratoia (BIO21/COV/037) and PID 2019-107956RA-I00.